4 Top Stocks to Buy in April
Here are four stocks to buy now that could offer investors upside in the short term and long term.
Be Alert to Investor Risks from SMS Phishing Scams
Learn how to protect yourself from one of the most prominent forms of cybersecurity attacks.
Better Buy in 2025: XRP ( Ripple ) or Dogecoin?
XRP and Dogecoin are emerging as increasingly popular investments in the cryptocurrency landscape.
Altria vs. Eli Lilly: What's the Better Stock for Dividend Investors?
Tobacco giant Altria ( NYSE: MO ) provides a tremendously high dividend yield of 7%, which is well above the S&P 500 index average of 1.3%. But it comes with risks, as its business has been struggling to grow in recent years, and its rate of dividend increases has been modest.Meanwhile, pharma ...
Tesla Stock Is Down Big in 2025. Buy, Sell, or Hold?
Tesla's brutal decline has shaken investors. Should you walk away or double down?
Is Rocket Lab Stock a Buy Now?
It's time to examine the numbers to evaluate this volatile stock's trajectory after it climbed 350% in the past year.
North Korean IT Workers Infiltrated European Solana-Based Projects: Google
Google Threat Intelligence warned that North Korean IT workers have worked on crypto projects in the EU and UK.
Good News for AMD Stock Investors
In this video, I will talk about recent updates regarding Advanced Micro Devices ( NASDAQ: AMD ) . Watch the short video to learn more, consider subscribing, and click the special offer link below.*Stock prices used were from the trading day of March 31, 2025.
VISTA Inhibitor Clinical Trials Market Size FDA Approval Patent Report 2025
Delhi, April 02, 2025 ( GLOBE NEWSWIRE ) -- Global VISTA Inhibitor Clinical Trials, Drug Development Opportunities & Patent Insight 2025 Report Highlights & Findings: First VISTA Inhibitor Drug Approval By 2028 US Dominating Global VISTA Inhibitor Clinical Trials Landscape







